Remove Bioavailability Remove Genetic Disease Remove Genetics
article thumbnail

Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO

XTalks

Jotrol overcomes these barriers using patented micellar technology, enhancing bioavailability and enabling therapeutically effective doses. CAMP4’s RNA-based therapies focus on genetic diseases like urea cycle disorders, while Rapport’s small molecules aim to address epilepsy, pain and bipolar disorder.

article thumbnail

Patient-Centered Innovation for Rare Seizure Disorders: Insights from Marinus Pharmaceuticals

XTalks

CDKL5 deficiency disorder (CDD) is a rare genetic condition caused by mutations in the CDKL5 gene, which is essential for brain development and function. They are exploring a prodrug formulation of ganaxolone to potentially enhance the patient experience and treatment effectiveness by aiming to improve the drug’s bioavailability.